Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients

Karolinska Institute

Status: Completed

Conditions: Thromboembolism; Covid19

Treatments: Drug: Dose of tinzaparin or dalteparin

Study type: Observational

Funder types: Other

Identifiers

NCT04593654

Thromboprophylaxis COVID-19

Details and patient eligibility

About

The aim of the study is to associate dose of thromboprophylaxis with outcome in critically ill COVID-19 patients. This will be done by associating dose of thromboprophylaxis with 28-day mortality, survival outside ICU, thromboembolic event and bleeding complications.This was done in our earlier study for patients admitted in March and April (Clinicaltrials.gov NCT04412304 June 2 2020) but now we will include the patients admitted in May, June and half of July and we will ad the outcome of 90-day mortality.

Enrollment: 257 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• laboratory confirmed positive test for SARS-CoV-2
• admitted to ICU because of respiratory failure caused by Covid-19

Exclusion criteria

• patients with treatment for thromboembolic complications at arrival to the ICU
• short ICU length of stay defined as discharged the same date as ICU admission
• patients without initial thromboprophylaxis

Trial design

257 participants in 3 patient groups

low dose thromboprophylaxis

Description:

Daily dose of 2500-4500 IU tinzaparin or 2500-5000 IU dalteparin

Treatment:

Drug: Dose of tinzaparin or dalteparin

medium dose thromboprophylaxis

Description:

Daily dose of \>4500 IU but \<175 IU/kg of body weight tinzaparin or \>5000 IU but \<200 IU/kg of body weight dalteparin

Treatment:

Drug: Dose of tinzaparin or dalteparin

high dose thromboprophylaxis

Description:

Daily dose of ≥ 175 IU/kg of body weight tinzaparin or ≥200 IU/kg of body weight dalteparin

Treatment:

Drug: Dose of tinzaparin or dalteparin